amlodipine + chlorthalidone + losartan

HCP1803-4 is a fixed-dose triple combination therapy developed by Hanmi Pharmaceutical for the treatment of essential hypertension. It consists of three established antihypertensive agents: amlodipine camsylate (a calcium channel blocker), losartan potassium (an angiotensin II receptor antagonist), and chlorthalidone (a thiazide-like diuretic). The HCP1803-4 formulation specifically refers to a strength containing 5 mg of amlodipine, 100 mg of losartan, and 25 mg of chlorthalidone. This combination targets multiple physiological pathways to lower blood pressure: amlodipine promotes peripheral vasodilation, losartan inhibits the vasoconstrictive effects of angiotensin II, and chlorthalidone reduces extracellular fluid volume through diuresis. The triple combination is intended for patients whose blood pressure is not adequately controlled by dual therapy, providing a more potent and convenient treatment option.

Brand names

Amosartan Plus

Other names

Amlodipine camsylate / Losartan potassium / ChlorthalidoneAmlodipine + Losartan + Chlorthalidone